Halozyme Falls as ViroPharma Cancels Mid-Stage Drug Trial

Halozyme Therapeutics Inc., a developer of drug-delivery systems, fell the most in a year after its partner ViroPharma Inc. ended a mid-stage trial of a therapy for a genetic disease that causes severe swelling.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.